You are here

Novo Nordisk Diabetes Drug Doesn’t Help Heart Failure, Study Finds

Victoza fails to help prevent heart failure in clinical trial

The Novo Nordisk diabetes drug liraglutide (Victoza, Novo Nordisk) failed to improve clinical stability or delay death in patients suffering from advanced heart failure, researchers reported at a medical meeting.

According to a Reuters report, the injectable drug was tested in 300 patients with and without type-2 diabetes who had advanced heart failure and a recent hospitalization. Researchers had hoped that the medicine's effect on blood sugar could mitigate some of the metabolic effects of heart failure.

However, they found no significant difference between a placebo and liraglutide in time to death or time to heart failure hospitalizations, according to data presented at the American Heart Association (AHA) scientific meeting in Orlando on November 8. The number of hospitalizations was higher in the liraglutide group, but that was not deemed to be statistically significant.

"We're disappointed this didn't work out, but it's important to understand heart failure and diabetes together as common problems," Dr. Adrian Hernandez, professor of medicine at Duke Clinical Research Institute and one of the study's lead researchers, said in an interview.

Heart failure, in which the heart becomes unable to pump enough blood, is among the many serious health problems associated with diabetes and is a leading cause of hospitalizations and death.

Novo Nordisk was not involved with the trial, called FIGHT, which was independently undertaken by researchers from the government-funded Heart Failure Clinical Research Network.

Liraglutide belongs to a class of diabetes drugs called synthetic glucagon-like peptide-1 (GLP-1) agonists that improve insulin sensitivity. Insulin resistance that impairs blood glucose function is one of the metabolic effects of heart failure, researchers explained.

Jardiance, an oral diabetes drug from Eli Lilly and Boehringer Ingelheim that belongs to a different class of medicines and works differently than liraglutide, reduced hospitalizations from heart failure by 35% in a separate study. "We haven't seen anything close to that in the past," Dr. Clyde Yancy, chief of cardiology at Northwestern University and a past AHA president, said about the Jardiance result.

Researchers were hoping for a similarly beneficial impact from liraglutide. Yancy said more studies of the impact of diabetes drugs on heart failure were needed.

The Novo Nordisk drug did improve blood sugar control and led to modest weight loss, as expected.

Source: Reuters, November 9, 2015.

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications
“Baltimore Score” Outperforms Existing Prediction Models